The mechanisms behind inflammation in conditions treated with TNF blockade involve the same pathways used in response to intracellular pathogens, causing increased susceptibility and severity of pneumonia in people living with these diseases (Wallis et al., 2004; Curtis et al., 2011). Here, TNF is linked to pneumonia.